Peptide Initiative

Peptides · Peptide comparison

Liraglutide vs Semaglutide

FDA-approved once-daily GLP-1 receptor agonist (Victoza/Saxenda) that reduces HbA1c by 0.9–1.6%, promotes 5–10% body weight loss, and demonstrated a 13% reduction in major adverse cardiovascular events in the landmark LEADER trial of 9,340 patients

The revolutionary once-weekly GLP-1 medication that helps your body feel full faster and longer, leading to significant weight loss while also protecting your heart—FDA approved and backed by some of the largest clinical trials in obesity medicine history.

  • Weight Management
  • Weight Management

At a glance

Quick comparison

Dose rangeLiraglutide1.2–1.8 mgSemaglutide0.5–1 mg
FrequencyLiraglutideOnce dailySemaglutideOnce weekly
AdministrationLiraglutideSubcutaneous injectionSemaglutideSubcutaneous injection
Cycle lengthLiraglutideOngoing/indefiniteSemaglutideOngoing/indefinite
Onset speedLiraglutideGradual (3-4 weeks)SemaglutideModerate (1-2 weeks)
Evidence levelLiraglutideStrong human trials (Phase 3 or FDA approved)SemaglutideStrong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Weight Management

Liraglutide9%
SemaglutideNo recorded rating

Metabolic

Liraglutide9%
SemaglutideNo recorded rating

Healing & Recovery

Liraglutide8%
SemaglutideNo recorded rating

Weight Loss

LiraglutideNo recorded rating
Semaglutide98%

Appetite Control

LiraglutideNo recorded rating
Semaglutide95%

Heart Protection

LiraglutideNo recorded rating
Semaglutide92%

Technical data

Compound specifications

Liraglutide

Molecular formula
C172H265N43O51
Molecular weight
3,751 Da
Half-life
~13 hours (enabling once-daily dosing); Tmax 8–12 hours; steady state in 3–5 days
Bioavailability
~55% after subcutaneous injection; >98% plasma protein binding to albumin via C16 fatty acid moiety
CAS number
204656-20-2

Semaglutide

Molecular formula
C187H291N45O59
Molecular weight
4113.58 g/mol
Half-life
Approximately 7 days (168 hours)
Bioavailability
89% (subcutaneous); 0.4-1% (oral, with absorption enhancer)
CAS number
910463-68-2

Protocols

Dosing compared

Liraglutide

Subcutaneous

  • Week 10.6 mgOnce daily · Week 1FDA-label starting dose for both Victoza (type 2 diabetes) and Saxenda (weight management); used for the first week to improve GI tolerability before escalation [6].
  • Ongoing1.2-1.8 mgOnce daily · OngoingVictoza maintenance range for type 2 diabetes; dose increased to 1.2 mg after week 1 and to 1.8 mg if further glycemic control is needed [6].
  • Ongoing3.0 mgOnce daily · OngoingSaxenda maintenance dose for chronic weight management, reached by escalating 0.6 mg weekly (0.6 to 1.2 to 1.8 to 2.4 to 3.0 mg over 5 weeks) [6].

Semaglutide

Subcutaneous

  • 4 weeks0.25 mgOnce weekly · 4 weeksThis is the starter dose to help your body adjust. It does not lower blood sugar much on its own, so it is only used for the first 4 weeks before stepping up [5].
  • At least 4 weeks at each step0.5-1 mgOnce weekly · At least 4 weeks at each stepAfter the starter month, the dose goes up to 0.5 mg, and can rise to 1 mg if more blood sugar control is needed. Wait at least 4 weeks before each increase [5].
  • Ongoing/maintenance2-2.4 mgOnce weekly · Ongoing/maintenanceThe highest weekly doses. 2 mg is the maximum for diabetes (Ozempic) [5]; up to 2.4 mg is used for weight management (Wegovy) after a slower titration.

Oral

  • 30 days3 mgOnce daily · 30 daysThe pill form (Rybelsus) starts at 3 mg each morning for 30 days. Like the starter shot, this dose is for getting started and does not control blood sugar by itself. Take on an empty stomach with a small sip of water, 30 minutes before food or other pills [6].
  • 30+ days7 mgOnce daily · 30+ daysAfter the first 30 days, the dose increases to 7 mg once daily. This is the first dose that actively lowers blood sugar [6].
  • Ongoing/maintenance14 mgOnce daily · Ongoing/maintenanceThe highest pill dose, used if more blood sugar control is needed after at least 30 days at 7 mg [6].

Applications

Best suited for

Liraglutide

Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
Liraglutide is particularly well-suited for individuals focused on type 2 diabetes patients with hba1c >7% requiring both glycemic control and weight management. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].
Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
Liraglutide is particularly well-suited for individuals focused on obese individuals (bmi ≥30) or overweight (bmi ≥27) with weight-related comorbidities seeking fda-approved pharmacotherapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [6].
Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
Liraglutide is particularly well-suited for individuals focused on patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [7].
Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile
Liraglutide is particularly well-suited for individuals focused on patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [3].

Semaglutide

People with Obesity Seeking Significant Weight Loss
If your BMI is 30 or higher (or 27+ with weight-related health conditions), semaglutide is currently one of the most effective non-surgical weight loss options available. [7] Clinical trials show average weight loss of 15% of body weight—that's 30+ pounds for someone starting at 200 pounds [1].
Those Who've Struggled with Diet and Exercise Alone
Semaglutide works by changing the biological signals that drive hunger and cravings. If you've tried to lose weight through willpower alone and found yourself constantly battling hunger, this medication addresses that underlying biology rather than just telling you to eat less [3][7][13].
People with Type 2 Diabetes Needing Better Control
Originally developed for diabetes, semaglutide excellently controls blood sugar while also promoting weight loss—addressing two major health concerns simultaneously. [3][5] It can often allow people to reduce or eliminate other diabetes medications [21].
Individuals at High Cardiovascular Risk
The SELECT trial proved that semaglutide reduces heart attacks, strokes, and cardiovascular death by 20% in people with obesity and existing heart disease—even without diabetes. It's one of the few weight loss medications proven to improve hard cardiovascular outcomes [2].

Safety profile

Side effects

Liraglutide

Common

  • Nausea
  • Diarrhea
  • Vomiting
  • Decreased appetite and headache

Uncommon

  • Injection site reactions

Serious

  • Acute pancreatitis
  • Gallbladder disease

Semaglutide

Common

  • Nausea
  • Constipation or Diarrhea
  • Decreased Appetite
  • Vomiting

Uncommon

  • Gallbladder Problems
  • Hair Loss (Telogen Effluvium)

Serious

  • Pancreatitis
  • Thyroid Tumors (Theoretical Risk)

Research status

Safety & evidence

Liraglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Liraglutide (Victoza, Saxenda) is FDA-approved with extensive safety data from 15+ years of clinical use in diabetes (GLP-1 agonist) and obesity indications. Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of patients during dose escalation [6] but diminish significantly after 2-3 weeks of stable dosing. Black box warnings include risk of medullary thyroid carcinoma and pancreatitis, though absolute incidence remains rare. Injection site reactions are minimal. The compound shows no hepatotoxicity, nephrotoxicity, or major drug interactions at approved doses.

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) — black box warning based on rodent thyroid C-cell tumor findings [6]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [6]
  • Known hypersensitivity to liraglutide or any excipients [6]

Semaglutide

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Semaglutide has been studied in over 20,000 participants across multiple large clinical trials, making it one of the most thoroughly researched weight loss medications available. [1][2][8][9][10] The FDA approved it after rigorous review of safety data. While GI side effects are common (especially early on), serious side effects are rare. [1][7] The SELECT trial showed it actually reduces cardiovascular events, adding a safety benefit beyond just weight loss [2].

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC) [7]
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [7]
  • History of serious allergic reaction to semaglutide [7]

Decision guide

Which is right for you?

Liraglutide

Choose Liraglutide if…

  • Type 2 diabetes patients with HbA1c >7% requiring both glycemic control and weight management
  • Obese individuals (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities seeking FDA-approved pharmacotherapy
  • Patients with established cardiovascular disease or high cardiovascular risk seeking cardioprotective diabetes therapy
  • Patients on metformin requiring add-on therapy with favorable weight and cardiovascular profile

Semaglutide

Choose Semaglutide if…

  • Significant weight loss
  • Long-term weight management
  • Cardiovascular risk reduction
  • Blood sugar control